Repligen Newsroom

Repligen Analyst Ratings

BenzingaJun 26 06:30 ET

RBC Cuts Price Target on Repligen to $190 From $221, Maintains Outperform Rating

MT NewswiresJun 24 06:32 ET

Repligen Analyst Ratings

BenzingaJun 18 06:47 ET

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)

TipRanksMay 3 07:50 ET

Repligen Analyst Ratings

BenzingaMay 2 12:47 ET

Repligen (RGEN) Gets a Buy From RBC Capital

TipRanksApr 30 21:50 ET

Craig-Hallum Sticks to Their Buy Rating for Repligen (RGEN)

TipRanksApr 29 09:01 ET

RBC Capital Remains a Buy on Repligen (RGEN)

TipRanksApr 8 21:52 ET

RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating

MT NewswiresApr 8 07:57 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immuneering (IMRX), Halozyme (HALO) and Repligen (RGEN)

TipRanksFeb 26 00:10 ET

Repligen Analyst Ratings

BenzingaFeb 22 14:03 ET

Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating

MT NewswiresFeb 22 11:22 ET

RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating

MT NewswiresFeb 22 07:43 ET

Repligen (RGEN) Receives a Buy From RBC Capital

TipRanksFeb 22 07:31 ET

Repligen (RGEN) Gets a Buy From Craig-Hallum

TipRanksFeb 20 08:39 ET

Repligen Analyst Ratings

BenzingaFeb 15 14:12 ET

Craig-Hallum Remains a Buy on Repligen (RGEN)

TipRanksFeb 15 08:46 ET

RBC Capital Sticks to Their Buy Rating for Repligen (RGEN)

TipRanksJan 26 20:46 ET

Repligen Analyst Ratings

BenzingaDec 20, 2023 15:18 ET

Deutsche Bank Adjusts Repligen Price Target to $175 From $150, Maintains Hold Rating

MT NewswiresDec 18, 2023 11:03 ET